Development, in vitro and in vivo characterization of zoledronic acid functionalized hydroxyapatite nanoparticle based formulation for treatment of osteoporosis in animal model

European Journal of Pharmaceutical Sciences

Volumn 66, Issue , 2015, Pages 173-183

  Khajuria, Deepak Kumar ^a,b   Razdan, Rema ^a   Mahapatra, Debiprosad Roy ^b  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Hydroxyapatite nanoparticles; Postmenopausal osteoporosis; Rat model; Zoledronic acid

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; HYDROXYAPATITE; NANOPARTICLE; OSTEOCALCIN; PROCOLLAGEN; PROCOLLAGEN TYPE I N TERMINAL PROPEPTIDE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; ZOLEDRONIC ACID HYDROXYAPATITE NANOPARTICLE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADSORPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BONE METABOLISM; BONE STRENGTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; FEMUR; IN VITRO STUDY; IN VIVO STUDY; LUMBAR SPINE; LUMBAR VERTEBRA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; RAT; SHAM PROCEDURE; WISTAR RAT; ANIMAL; CHEMISTRY; DOSE RESPONSE; OSTEOPOROSIS; RANDOMIZATION;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DURAPATITE; FEMALE; IMIDAZOLES; NANOPARTICLES; OSTEOPOROSIS; OVARIECTOMY; RANDOM ALLOCATION; RATS;

EID: 84910058592     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2014.10.015     Document Type: Article

References (39)

1. H. Aoki, T. Kutsuno, W. Li, and M. Niwa An in vivo study on the reaction of hydroxyapatite-sol injected into blood J. Mater. Sci. Mater. Med. 11 2000 67 72
2. D. Apelt, F. Theiss, A.O. El-Warrak, K. Zlinszky, R. Bettschart-Wolfisberger, M. Bohner, S. Matter, J.A. Auer, and B. von Rechenberg In vivo behavior of three different injectable hydraulic calcium phosphate cements Biomaterials 25 2004 1439 1451
3. N.V. Becerril, L.T. Jurado, and L.M. Rodriguez-Lorenzo Adsorption of fibronectin on hydroxyapatite functionalized with alendronate J. Aust. Ceram. Soc. 49 2013 112 118
4. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, and S.R. Cummings Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N. Engl. J. Med. 356 2007 1809 1822
5. E. Boaninia, P. Torricellib, M. Gazzanoc, R. Giardinob, and A. Bigia Alendronate hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells Biomaterials 29 2008 790 796
6. M.H. Fathia, A.V. Hanifia, and V. Mortazavi Preparation and bioactivity evaluation of bone-like hydroxyapatite nanopowder J. Mater. Proc. Technol. 202 2008 536 542
7. A. Fernandez-Pareja, E. Hernandez-Blanco, J.M. Perez-Maceda, V.J.R. Riera, J.H. Palazuelos, and J.M. Dalmau Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound Clin. Drug Invest. 27 2007 227 232
8. K. Fox, P.A. Tran, and N. Tran Recent advances in research applications of nanophase hydroxyapatite ChemPhysChem 13 2012 2495 2506
9. A.J. Gomes, A.S. Faustino, C.N. Lunardi, L.O. Lunardi, and A.E.H. Machado Evaluation of nanoparticles loaded with benzopsoralen in rat peritoneal exudate cells Int. J. Pharm. 332 2007 153 160
10. V. Hengst, C. Oussoren, T. Kissel, and G. Storm Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro Int. J. Pharm. 331 2007 224 227
11. O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos. Int. 17 2006 1726 1733
12. D.K. Kalu, C.C. Liu, and E. Salerno Skeletal response of ovariectomized rats to low and high doses of 17b-estradiol Bone Miner. 1991 1991 175 187
13. D.K. Khajuria, R. Razdan, and D.R. Mahapatra Drugs for the management of osteoporosis: a review Rev. Bras. Reumatol. 51 2011 365 382
14. D.K. Khajuria, R. Razdan, and D.R. Mahapatra Description of a new method of ovariectomy in female rats Rev. Bras. Reumatol. 52 2012 466 470
15. D.K. Khajuria, R. Razdan, D.R. Mahapatra, and M.R. Bhat Osteoprotective effect of propranolol in ovariectomized rats: a comparison with zoledronic acid and alfacalcidol J. Orthop. Sci. 18 2013 832 842
16. D.K. Khajuria, C. Disha, R. Razdan, and D.R. Mahapatra Comparative evaluation of zoledronic acid, alfacalcidol, and propranolol in pharmacological correction of experimental osteoporosis Lat. Am. J. Pharm. 32 2013 968 976
17. D.K. Khajuria, C. Disha, R. Razdan, D.R. Mahapatra, and R. Vasireddi Prophylactic effects of propranolol versus standard therapy on a new model of disuse osteoporosis in rats Sci. Pharm. 2013 10 10.3797/scipharm,1310-06 (in press)
18. D.K. Khajuria, R. Razdan, and D.R. Mahapatra Zoledronic acid in combination with alfacalcidol has additive effects on trabecular microarchitecture and mechanical properties in osteopenic ovariectomized rats J. Orthop. Sci. 2014 10 10.1007/s00776-014-0557-8 (in press)
19. D.K. Khajuria, R. Razdan, and D.R. Mahapatra The combination therapy with zoledronic acid and propranolol improves the trabecular microarchitecture and mechanical property in an rat model of postmenopausal osteoporosis J. Osteoporos. 2014 2014 586431
20. O.V. Leppanen, H. Sievanen, and T.L. Jarvinen Biomechanical testing in experimental bone interventions - May the power be with you J. Biomech. 41 2008 1623 1631
21. L. Lin, K.L. Chow, and Y. Leng Study of hydroxyapatite osteoinductivity with an osteogenic differentiation of mesenchymal stem cells J. Biomed. Mater. Res. A 89 2009 326 335
22. L.P. Liu, Y.B. Xiao, Z.W. Xiao, Z.B. Wang, C. Li, and X. Gong Toxicity of hydroxyapatite nanoparticles on rabbits Wei Sheng Yan Jiu 34 2005 474 476
23. T.Y. Liu, S.Y. Chen, D.M. Liu, and S.C. Liou On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery J. Controlled Release 107 2005 112 121
24. K. McLeod, G.I. Anderson, N.K. Dutta, R.S. Smart, N.H. Voelcker, R. Sekel, and S. Kumar Adsorption of bisphosphonate onto hydroxyapatite using a novel co-precipitation technique for bone growth enhancement J. Biomed. Mater. Res. A 79 2006 271 281
25. H.T. Ong, J.S.C. Loo, F.Y.C. Boey, S.J. Russell, J. Ma, and K. Peng Exploiting the high-affinity phosphonate-hydroxyapatite nanoparticle interaction for delivery of radiation and drugs J. Nanopart. Res. 10 2008 141 150
26. E.M. Ooms, J.G. Wolke, M.T. van de Heuvel, B. Jeschke, and J.A. Jansen Histological evaluation of the bone response to calcium phosphate cement implanted in cortical bone Biomaterials 24 2003 989 1000
27. S.E. Papapoulos Bisphosphonates: how do they work? Best Pract. Res. Clin. Endocrinol. Metab. 22 2008 831 847
28. R. Pignatello, E. Cenni, D. Micieli, C. Fotia, M. Salerno, D. Granchi, S. Avnet, M.G. Sarpietro, F. Castelli, and N. Baldini A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate Nanomedicine (London) 4 2009 161 175
29. R.A. Power, U.T. Iwaniec, K.A. Magee, N.G. Mitova-Caneva, and T.J. Wronski Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats Osteoporos. Int. 15 2004 716 723
30. B.M. Rao, M.K. Srinivasu, C.P. Rani, S.S. Kumar, P.R. Kumar, K.B. Chandrasekhar, and M. Veerender A validated stability indicating ion-pair RP-LC method for zoledronic acid J. Pharm. Biomed. Anal. 39 2005 781 790
31. M. Regi, F. Balas, M. Colilla, and M. Manzano Drug confinement and delivery in ceramic implants Drug Metab. Lett. 1 2007 37 40
32. A.J. Roelofs, K. Thompson, S. Gordon, and M.J. Rogers Molecular mechanisms of action of bisphosphonates: current status Clin. Cancer Res. 12 2006 6222s 6230s
33. A. Saleh, V.V. Hegde, A.G. Potty, and J.M. Lane Bisphosphonate therapy and atypical fractures Orthop. Clin. North Am. 44 2013 137 151
34. S.S. Shirke, S.R. Jadhav, and A.G. Jagtap Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats Exp. Biol. Med. 233 2008 1403 1410
35. F.R. Singer, and D.R. Eyre Using biochemical markers of bone turnover in clinical practice Cleve. Clin. J. Med. 75 2008 739 750
36. T.C. Sorensen, J. Arnoldi, P. Procter, B. Robioneck, and H. Steckel Bone substitute materials delivering zoledronic acid: physicochemical characterization, drug load, and release properties J. Biomater. Appl. 27 2013 727 738
37. H. Sun, F. Ye, J. Wang, Y. Shi, Z. Tu, J. Bao, M. Qin, H. Bu, and Y. Li The upregulation of osteoblast marker genes in mesenchymal stem cells prove the osteoinductivity of hydroxyapatite/tricalcium phosphate biomaterial Transplant. Proc. 40 2008 2645 2648
38. F. Ye, H. Guo, H. Zhang, and X.H. Xiulan Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system Acta Biomater. 6 2010 2212 2218
39. Y. Zhang, W.P. Lai, P.C. Leung, C.F. Wu, and M.S. Wong Short-to mid term effects of ovariectomy on bone turnover, bone mass and bone strength in rats Biol. Pharm. Bull. 30 2007 898 903